Immune checkpoint inhibitors targeting cell death ligand-L1(PD-L1), programmed cell death-1 (PD-1), cytotoxic T-lymphocyte antigen-4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3) have substantially improved the cure and the management of several forms of cancer. This evidence concerns the gene LAG3 and cancer.